Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type II diabetes

Chen-pin Wang, Donna M Lehman, Yui-wing F Lam, John G. Kuhn, Devalingam Mahalingam, Steven D Weitman, Carlos Lorenzo, John R Downs, Elizabeth A. Stuart, Javier Hernandez, Ian M. Thompson, Amelie G Ramirez

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Racial/ethnic disparity in prostate cancer is under studied in men with diabetes who are at a higher risk of aggressive prostate cancer. This study assessed the race/ethnic disparity in prostate cancer incidence for men with type II diabetes (T2D) and whether the impact of metformin on prostate cancer incidence varied by race/ethnicity. We conducted a retrospective study in 76,733 male veterans with T2D during 2003 to 2012. Cox proportional hazards model adjusting for covariates and propensity scores of metformin use and race/ethnic group membership was utilized to compute the HR of prostate cancer incidence associated with race/ethnicity and compare HR associated with metformin use between race/ethnic groups. Mean follow-up was 6.4 ± 2.8 years; 7% were Hispanics; 17% were African Americans (AA); mean age was 67.8 ± 9.8 years; 5.2% developed prostate cancer; and 38.9% used metformin. Among these diabetic men without metformin use, prostate cancer incidence was higher in Hispanics and AA than in non-Hispanic White (NHW). Use of metformin alone or metformin + statins was associated with a greater prostate cancer incidence reduction in Hispanics compared with NHW, but not between AA and NHW. Use of metformin + finasteride was associated with a greater prostate cancer incidence reduction in Hispanics and AA compared with NHW. Our results suggested that metformin treatment could be a potential strategy to reduce prostate cancer incidence in the minority populations who are at high risk for fatal prostate cancer. It will be important to further examine the pleiotropic effects of metformin in multi-race/ethnic prospective studies to better inform clinical management and potentially reduce racial/ethnic disparity in prostate cancer incidence among diabetic men.

Original languageEnglish (US)
Pages (from-to)779-787
Number of pages9
JournalCancer Prevention Research
Volume9
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Metformin
Type 2 Diabetes Mellitus
Prostatic Neoplasms
Incidence
Hispanic Americans
African Americans
Ethnic Groups
Finasteride
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Propensity Score
Veterans
Proportional Hazards Models
Retrospective Studies
Prospective Studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type II diabetes. / Wang, Chen-pin; Lehman, Donna M; Lam, Yui-wing F; Kuhn, John G.; Mahalingam, Devalingam; Weitman, Steven D; Lorenzo, Carlos; Downs, John R; Stuart, Elizabeth A.; Hernandez, Javier; Thompson, Ian M.; Ramirez, Amelie G.

In: Cancer Prevention Research, Vol. 9, No. 10, 01.10.2016, p. 779-787.

Research output: Contribution to journalArticle

Wang, C, Lehman, DM, Lam, YF, Kuhn, JG, Mahalingam, D, Weitman, SD, Lorenzo, C, Downs, JR, Stuart, EA, Hernandez, J, Thompson, IM & Ramirez, AG 2016, 'Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type II diabetes', Cancer Prevention Research, vol. 9, no. 10, pp. 779-787. https://doi.org/10.1158/1940-6207.CAPR-15-0425
Wang, Chen-pin ; Lehman, Donna M ; Lam, Yui-wing F ; Kuhn, John G. ; Mahalingam, Devalingam ; Weitman, Steven D ; Lorenzo, Carlos ; Downs, John R ; Stuart, Elizabeth A. ; Hernandez, Javier ; Thompson, Ian M. ; Ramirez, Amelie G. / Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type II diabetes. In: Cancer Prevention Research. 2016 ; Vol. 9, No. 10. pp. 779-787.
@article{c32253c600ee4477bf31427737dafed5,
title = "Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type II diabetes",
abstract = "Racial/ethnic disparity in prostate cancer is under studied in men with diabetes who are at a higher risk of aggressive prostate cancer. This study assessed the race/ethnic disparity in prostate cancer incidence for men with type II diabetes (T2D) and whether the impact of metformin on prostate cancer incidence varied by race/ethnicity. We conducted a retrospective study in 76,733 male veterans with T2D during 2003 to 2012. Cox proportional hazards model adjusting for covariates and propensity scores of metformin use and race/ethnic group membership was utilized to compute the HR of prostate cancer incidence associated with race/ethnicity and compare HR associated with metformin use between race/ethnic groups. Mean follow-up was 6.4 ± 2.8 years; 7{\%} were Hispanics; 17{\%} were African Americans (AA); mean age was 67.8 ± 9.8 years; 5.2{\%} developed prostate cancer; and 38.9{\%} used metformin. Among these diabetic men without metformin use, prostate cancer incidence was higher in Hispanics and AA than in non-Hispanic White (NHW). Use of metformin alone or metformin + statins was associated with a greater prostate cancer incidence reduction in Hispanics compared with NHW, but not between AA and NHW. Use of metformin + finasteride was associated with a greater prostate cancer incidence reduction in Hispanics and AA compared with NHW. Our results suggested that metformin treatment could be a potential strategy to reduce prostate cancer incidence in the minority populations who are at high risk for fatal prostate cancer. It will be important to further examine the pleiotropic effects of metformin in multi-race/ethnic prospective studies to better inform clinical management and potentially reduce racial/ethnic disparity in prostate cancer incidence among diabetic men.",
author = "Chen-pin Wang and Lehman, {Donna M} and Lam, {Yui-wing F} and Kuhn, {John G.} and Devalingam Mahalingam and Weitman, {Steven D} and Carlos Lorenzo and Downs, {John R} and Stuart, {Elizabeth A.} and Javier Hernandez and Thompson, {Ian M.} and Ramirez, {Amelie G}",
year = "2016",
month = "10",
day = "1",
doi = "10.1158/1940-6207.CAPR-15-0425",
language = "English (US)",
volume = "9",
pages = "779--787",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Metformin for reducing racial/ethnic difference in prostate cancer incidence for men with type II diabetes

AU - Wang, Chen-pin

AU - Lehman, Donna M

AU - Lam, Yui-wing F

AU - Kuhn, John G.

AU - Mahalingam, Devalingam

AU - Weitman, Steven D

AU - Lorenzo, Carlos

AU - Downs, John R

AU - Stuart, Elizabeth A.

AU - Hernandez, Javier

AU - Thompson, Ian M.

AU - Ramirez, Amelie G

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Racial/ethnic disparity in prostate cancer is under studied in men with diabetes who are at a higher risk of aggressive prostate cancer. This study assessed the race/ethnic disparity in prostate cancer incidence for men with type II diabetes (T2D) and whether the impact of metformin on prostate cancer incidence varied by race/ethnicity. We conducted a retrospective study in 76,733 male veterans with T2D during 2003 to 2012. Cox proportional hazards model adjusting for covariates and propensity scores of metformin use and race/ethnic group membership was utilized to compute the HR of prostate cancer incidence associated with race/ethnicity and compare HR associated with metformin use between race/ethnic groups. Mean follow-up was 6.4 ± 2.8 years; 7% were Hispanics; 17% were African Americans (AA); mean age was 67.8 ± 9.8 years; 5.2% developed prostate cancer; and 38.9% used metformin. Among these diabetic men without metformin use, prostate cancer incidence was higher in Hispanics and AA than in non-Hispanic White (NHW). Use of metformin alone or metformin + statins was associated with a greater prostate cancer incidence reduction in Hispanics compared with NHW, but not between AA and NHW. Use of metformin + finasteride was associated with a greater prostate cancer incidence reduction in Hispanics and AA compared with NHW. Our results suggested that metformin treatment could be a potential strategy to reduce prostate cancer incidence in the minority populations who are at high risk for fatal prostate cancer. It will be important to further examine the pleiotropic effects of metformin in multi-race/ethnic prospective studies to better inform clinical management and potentially reduce racial/ethnic disparity in prostate cancer incidence among diabetic men.

AB - Racial/ethnic disparity in prostate cancer is under studied in men with diabetes who are at a higher risk of aggressive prostate cancer. This study assessed the race/ethnic disparity in prostate cancer incidence for men with type II diabetes (T2D) and whether the impact of metformin on prostate cancer incidence varied by race/ethnicity. We conducted a retrospective study in 76,733 male veterans with T2D during 2003 to 2012. Cox proportional hazards model adjusting for covariates and propensity scores of metformin use and race/ethnic group membership was utilized to compute the HR of prostate cancer incidence associated with race/ethnicity and compare HR associated with metformin use between race/ethnic groups. Mean follow-up was 6.4 ± 2.8 years; 7% were Hispanics; 17% were African Americans (AA); mean age was 67.8 ± 9.8 years; 5.2% developed prostate cancer; and 38.9% used metformin. Among these diabetic men without metformin use, prostate cancer incidence was higher in Hispanics and AA than in non-Hispanic White (NHW). Use of metformin alone or metformin + statins was associated with a greater prostate cancer incidence reduction in Hispanics compared with NHW, but not between AA and NHW. Use of metformin + finasteride was associated with a greater prostate cancer incidence reduction in Hispanics and AA compared with NHW. Our results suggested that metformin treatment could be a potential strategy to reduce prostate cancer incidence in the minority populations who are at high risk for fatal prostate cancer. It will be important to further examine the pleiotropic effects of metformin in multi-race/ethnic prospective studies to better inform clinical management and potentially reduce racial/ethnic disparity in prostate cancer incidence among diabetic men.

UR - http://www.scopus.com/inward/record.url?scp=84991706641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991706641&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-15-0425

DO - 10.1158/1940-6207.CAPR-15-0425

M3 - Article

VL - 9

SP - 779

EP - 787

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 10

ER -